Published in J Neurooncol on September 12, 2008
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57
Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des (2011) 1.47
The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res (2009) 1.25
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A (2011) 1.24
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos (2012) 1.19
Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol (2011) 1.14
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res (2010) 1.00
Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther (2012) 0.94
Brain microdialysis study of meropenem in two patients with acute brain injury. Antimicrob Agents Chemother (2010) 0.90
Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol (2013) 0.88
Analytical and biological methods for probing the blood-brain barrier. Annu Rev Anal Chem (Palo Alto Calif) (2012) 0.86
Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development. Expert Opin Drug Metab Toxicol (2010) 0.86
Blood-based biomarkers for malignant gliomas. J Neurooncol (2013) 0.84
Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos (2013) 0.84
Cerebral microdialysis in clinical studies of drugs: pharmacokinetic applications. J Pharmacokinet Pharmacodyn (2013) 0.83
Microdialysis study of cefotaxime cerebral distribution in patients with acute brain injury. Antimicrob Agents Chemother (2013) 0.82
Microdialysis combined with proteomics for protein identification in breast tumor microenvironment in vivo. Cancer Microenviron (2010) 0.82
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Cancer Chemother Pharmacol (2012) 0.82
Recent advances in treatment of primary central nervous system lymphoma. Curr Treat Options Oncol (2013) 0.81
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. Cancer Chemother Pharmacol (2013) 0.81
Complete radiologic response and long-term survival with use of systemic high-dose methotrexate for breast cancer-associated leptomeningeal disease. Clin Breast Cancer (2012) 0.80
A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. Eur J Cancer (2013) 0.79
Clinical microdialysis in neuro-oncology: principles and applications. Chin J Cancer (2011) 0.78
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther (2015) 0.77
Magnetic resonance imaging-guided microdialysis cannula implantation in a spontaneous high-grade glioma murine model. J Pharm Sci (2011) 0.77
Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clin Pharmacokinet (2016) 0.76
Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases. Anticancer Agents Med Chem (2016) 0.76
A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent. J Neurooncol (2014) 0.76
Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine. Biomed Chromatogr (2013) 0.75
Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases. Int J Mol Sci (2016) 0.75
The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain. Drug Metab Dispos (2014) 0.75
In vivo online magnetic resonance quantification of absolute metabolite concentrations in microdialysate. Sci Rep (2016) 0.75
Barriers to drug delivery in solid tumors. Sci Am (1994) 3.57
Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol (2007) 2.93
Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol (2007) 2.66
Recent advances in the treatment of malignant astrocytoma. J Clin Oncol (2006) 2.55
Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther (2007) 1.74
Mechanisms of disease: the blood-brain barrier. Neurosurgery (2004) 1.72
Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology (1988) 1.65
MR contrast enhancement of intracranial lesions with Gd-DTPA. Radiol Clin North Am (1988) 1.57
Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg (2002) 1.47
Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res (1995) 1.46
Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agents Chemother (1998) 1.37
Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol (2006) 1.32
Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet (2002) 1.23
Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet (2006) 1.20
Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol (2007) 1.18
Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol (1999) 1.14
Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev (1997) 1.13
Microdialysis in neurointensive care. Curr Pharm Des (2004) 1.03
Methods to assess drug permeability across the blood-brain barrier. J Pharm Pharmacol (2006) 0.98
Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol (1992) 0.93
Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting. J Neurooncol (2006) 0.92
In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol (1996) 0.91
Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. J Neurooncol (2005) 0.89
The use of microdialysis in pharmacokinetics and pharmacodynamics. Pharmacotherapy (1997) 0.88
Continuous monitoring of blood-brain barrier opening to Cr51-EDTA by microdialysis following probe injury. Acta Neurochir Suppl (Wien) (1990) 0.86
Detection of cathepsin S cysteine protease in human brain tumour microdialysates in vivo. Br J Neurosurg (2007) 0.85
High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. Acta Oncol (2005) 0.84
The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain. Pharm Res (1995) 0.82
Pharmacokinetics of methotrexate in the extracellular fluid of brain C6-glioma after intravenous infusion in rats. Pharm Res (1999) 0.81
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res (1998) 0.80
In vitro and in vivo protein binding of methotrexate assessed by microdialysis. Int J Clin Pharmacol Ther (1996) 0.80
Determination of free extracellular levels of methotrexate by microdialysis in muscle and solid tumor of the rabbit. Pharm Res (1998) 0.80
Radionuclide imaging in drug development. Curr Pharm Des (2004) 0.80
Intracerebral microdialysis and its clinical application: a review. Methods (2001) 0.78
Protein binding of methotrexate to human albumin and serum. A first derivative spectroscopic analysis. Arzneimittelforschung (1991) 0.78
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol (2007) 3.34
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol (2003) 2.30
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol (2002) 2.10
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol (2004) 2.03
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg (2009) 1.91
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.91
Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res (2003) 1.79
Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res (2002) 1.78
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2005) 1.63
Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res (2008) 1.52
Surgical outcome following resection of contrast-enhanced pediatric brainstem gliomas. Pediatr Neurosurg (2003) 1.51
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. Proc Natl Acad Sci U S A (2010) 1.51
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery (2002) 1.50
The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol (2006) 1.45
The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest (2012) 1.39
Outcome of Chiari-associated syringomyelia after hindbrain decompression in children: analysis of 49 consecutive cases. Neurosurgery (2008) 1.34
Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J Clin Oncol (2003) 1.32
Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas. J Neurooncol (2012) 1.32
The genus Scutellaria an ethnopharmacological and phytochemical review. J Ethnopharmacol (2010) 1.32
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol (2007) 1.31
Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol (2009) 1.30
Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res (2004) 1.30
Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest (2013) 1.27
The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol (2015) 1.23
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer (2012) 1.21
A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res (2012) 1.21
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer (2005) 1.19
Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget (2012) 1.17
Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target. Nat Chem Biol (2011) 1.17
Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol (2005) 1.16
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol (2005) 1.16
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res (2013) 1.16
Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg (2003) 1.15
Multicentric parenchymal xanthogranuloma in a child: case report and review of the literature. Neurosurgery (2002) 1.14
Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol (2011) 1.14
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol (2010) 1.13
Controversies in the adjuvant therapy of high-grade gliomas. Oncologist (2011) 1.12
Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol (2006) 1.12
Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol (2003) 1.12
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol (2012) 1.11
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol (2010) 1.10
Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology (2008) 1.08
An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J Neurosurg (2003) 1.06
ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer (2004) 1.03
Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest (2006) 1.02
Management of pineal region tumors. Curr Treat Options Oncol (2006) 1.02
Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol (2006) 0.99
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol (2005) 0.99
Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS Oncol (2012) 0.98
Exposure to phytoestrogens in the perinatal period affects androgen secretion by testicular Leydig cells in the adult rat. Endocrinology (2007) 0.98
Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest (2004) 0.98
Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. J Clin Endocrinol Metab (2007) 0.98
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol (2009) 0.98
Penetration of intra-arterially administered vincristine in experimental brain tumor. Neuro Oncol (2004) 0.97
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer (2003) 0.97
Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood (2009) 0.97
Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity. J Invest Dermatol (2011) 0.96
Initial response to glucocorticoids. Cancer (2006) 0.95
Differential expression between pilocytic and anaplastic astrocytomas: identification of apolipoprotein D as a marker for low-grade, non-infiltrating primary CNS neoplasms. J Neuropathol Exp Neurol (2002) 0.95
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol (2002) 0.95
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer (2009) 0.95
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer (2006) 0.95
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. Blood (2013) 0.95
Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature. Cancer Invest (2006) 0.94
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer (2006) 0.94
Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck (2014) 0.94
A radiotherapy technique to limit dose to neural progenitor cell niches without compromising tumor coverage. J Neurooncol (2011) 0.93
Analysis and exploration of the use of rule-based algorithms and consensus methods for the inferral of haplotypes. Genetics (2003) 0.93
Comparison of shunt infection incidence in high-risk subgroups receiving antibiotic-impregnated versus standard shunts. Childs Nerv Syst (2008) 0.93
Treatment of glioblastoma in "elderly" patients. Curr Treat Options Oncol (2011) 0.92
The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res (2006) 0.92
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol (2004) 0.92
Adjustable vs set-pressure valves decrease the risk of proximal shunt obstruction in the treatment of pediatric hydrocephalus. Childs Nerv Syst (2006) 0.91
Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J Neurooncol (2002) 0.91
Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol (2012) 0.90
The efficacy of intravenous patient-controlled analgesia after intracranial surgery of the posterior fossa: a prospective, randomized controlled trial. Anesth Analg (2011) 0.90
Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest New Drugs (2006) 0.89
Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro Oncol (2004) 0.89
Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. Neurol Res (2012) 0.88
High outpatient pain intensity scores predict impending hospital admissions in patients with cancer. J Pain Symptom Manage (2009) 0.88
Facile stereospecific synthesis and biological evaluation of (S)- and (R)-2-amino-2-methyl-4-[123I]iodo-3-(E)-butenoic acid for brain tumor imaging with single photon emission computerized tomography. J Med Chem (2007) 0.88